Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $3.7 billion.

  • Gsk's Income from Continuing Operations rose 446187.52% to $3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 billion, marking a year-over-year increase of 3917.9%. This contributed to the annual value of $3.8 billion for FY2024, which is 4286.48% down from last year.
  • As of Q3 2025, Gsk's Income from Continuing Operations stood at $3.7 billion, which was up 446187.52% from $2.8 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Income from Continuing Operations peaked at $5.8 billion during Q4 2023, and registered a low of $81.9 million during Q3 2024.
  • Moreover, its 5-year median value for Income from Continuing Operations was $2.6 billion (2023), whereas its average is $2.5 billion.
  • As far as peak fluctuations go, Gsk's Income from Continuing Operations crashed by 9684.46% in 2024, and later surged by 446187.52% in 2025.
  • Over the past 5 years, Gsk's Income from Continuing Operations (Quarter) stood at $250.7 million in 2021, then surged by 1629.48% to $4.3 billion in 2022, then surged by 33.09% to $5.8 billion in 2023, then fell by 24.92% to $4.3 billion in 2024, then fell by 13.82% to $3.7 billion in 2025.
  • Its last three reported values are $3.7 billion in Q3 2025, $2.8 billion for Q2 2025, and $3.1 billion during Q1 2025.